Sartorius Stedim Biotech : The underlying trend is to the upside
Entry price :
320.2€ | Target : 400.14€ | Stop-loss : 276€ | Potential : 24.97%
Sartorius Stedim Biotech's shares display attractive technical aspects to anticipate a comeback of the underlying trend. Investors have an opportunity to buy the stock and target the € 400.14.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years. The company returns high margins, thereby supporting business profitability. The company is in a robust financial situation considering its net cash and margin position. Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases. Over the last 4 months, analysts have significantly revised upwards the company's estimated sales. Over the last twelve months, the sales forecast has been frequently revised upwards. For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before. For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year. Within the weekly time frame the stock shows a bullish technical configuration above the support level at 222.2 EUR
Based on current prices, the company has particularly high valuation levels. The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 94.67 times its estimated earnings per share for the ongoing year. The firm pays small or no dividend to shareholders. For that reason, it is not a yield company. The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Subsector Medical Equipment, Supplies & Distribution - NEC
1st jan. Capitalization (M$) Investor Rating
SARTORIUS STEDIM BIOTECH 6.46% 34 549
© MarketScreener.com 2020
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.
1 877 M
2 267 M
2 267 M
Net income 2020
Net Debt 2020
P/E ratio 2020
28 576 M
34 549 M
34 505 M
EV / Sales 2020
EV / Sales 2021
Nbr of Employees
Upcoming event on SARTORIUS STEDIM BIOTECH
Number of Analysts
Average target price
Last Close Price
Spread / Highest target
Spread / Average Target
Spread / Lowest Target